Stern Cardiovascular Research Success with The AngelMed Guardian System

Stern Cardiovascular Research participated in the ALERTS clinical trial using the AngelMed Guardian system, an implantable cardiac device designed to detect rapid ST segment changes. These ST segment changes may signify major cardiac events, such as coronary artery occlusions caused by life-threatening vulnerable plaque ruptures. Once an ST shift is detected, the system alerts patients to seek medical care by providing a series of vibratory, auditory, and visual warnings.

Headed at Stern Cardiovascular by Dr. Frank McGrew with implants performed by Dr. Eric Johnson, we were able to successfully follow multiple patients with the device and begin immediate care of these patients in the event of a myocardial infarction. The device has now received FDA approval for commercial use.

About The AngelMed Guardian System

The AngelMed Guardian System is an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The Guardian System is indicated for use in patients who have had prior acute coronary syndrome (ACS) events and who remain at high risk for recurrent ACS events.

The Guardian System is indicated as an adjunct to patient recognized symptoms. The Guardian System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events.

In the absence of symptoms, the Guardian System may identify asymptomatic ACS events and prompt the patient to seek medical attention.